-
Administrative Supplement for Research on Bioethical Issues
(PA-19-217)
National Institutes of Health
National Institute on Alcohol Abuse and Alcoholism
National Institute on Aging
National Institute of Arthritis and Musculoskeletal and Skin Diseases
National Cancer Institute
National Institute on Deafness and Other Communication Disorders
National Institute of Dental and Craniofacial Research
National Institute of Diabetes and Digestive and Kidney Diseases
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Human Genome Research Institute
National Heart, Lung, and Blood Institute
National Institute of Mental Health
National Institute of Nursing Research
National Institute of Neurological Disorders and Stroke
National Center for Advancing Translational Sciences
John E. Fogarty International Center
National Institute of Biomedical Imaging and Bioengineering
National Institute on Minority Health and Health Disparities
National Center for Advancing Translational Sciences
Application Receipt Date(s): May 13, 2019, by 5:00 PM local time of applicant organization.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Advancing Manufacturing Processing and Control Strategies for Drug Substances and Drug Products (U01)- Clinical Trial Optional
(PAR-19-216)
Food and Drug Administration
Application Receipt Date(s): May 14, 2019, by 11:59 PM Eastern Time.
April 4, 2020, by 11:59 PM Eastern Time.
April 5, 2021, by 11:59 PM Eastern Time.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date.
Late applications will not be accepted for this FOA.
-
Undergraduate Research Training Initiative for Student Enhancement (U-RISE) (T34)
(PAR-19-218)
National Institute of General Medical Sciences
Application Receipt Date(s): May 21, 2019; May 21, 2020; May 21, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Maximizing Access to Research Careers (T34)
(PAR-19-219)
National Institute of General Medical Sciences
Application Receipt Date(s): May 21, 2019; May 21, 2020; May 21, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases (U01 Clinical Trial Not Allowed)
(PAR-19-220)
National Institute of Neurological Disorders and Stroke
National Center for Advancing Translational Sciences
National Center for Advancing Translational Sciences
Application Receipt Date(s): August 14, 2019; February 19, 2020; August 19, 2020; February 17, 2021; August 18, 2021; February 16, 2022
by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
-
U.S.-South Africa Program for Collaborative Biomedical Research - Phase 2 (HIV/AIDS) (R01 Clinical Trial Optional)
(RFA-AI-19-022)
National Institute of Allergy and Infectious Diseases
National Institute on Alcohol Abuse and Alcoholism
National Cancer Institute
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute of Mental Health
Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date listed below.
-
U.S.-South Africa Program for Collaborative Biomedical Research - Phase 2 (HIV/AIDS) (U01 Clinical Trial Optional)
(RFA-AI-19-023)
National Institute of Allergy and Infectious Diseases
National Cancer Institute
Eunice Kennedy Shriver National Institute of Child Health and Human Development
Application Receipt Date(s): Only accepting applications for the AIDS Application Due Date listed below.
-
U.S.-South Africa Program for Collaborative Biomedical Research - Phase 2 (Infectious Diseases) (R01 Clinical Trial Optional)
(RFA-AI-19-024)
National Institute of Allergy and Infectious Diseases
Application Receipt Date(s): July 26, 2019 , by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
U.S.-South Africa Program for Collaborative Biomedical Research - Phase 2 (Infectious Diseases) (U01 Clinical Trial Optional)
(RFA-AI-19-025)
National Institute of Allergy and Infectious Diseases
Application Receipt Date(s): July 26, 2019 , by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities (P20 Clinical Trial Optional)
(RFA-CA-19-034)
National Cancer Institute
Application Receipt Date(s): June 19, 2019, October 18, 2019, June 19, 2020, and October 18, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
No late applications will be accepted for this Funding Opportunity Announcement .
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Limited Competition: Dental, Oral and Craniofacial Tissue Regeneration Consortium (U24 Clinical Trial Not Allowed)
(RFA-DE-19-010)
National Institute of Dental and Craniofacial Research
Application Receipt Date(s): June 11, 2019 by 5:00 PM local time of applicant organization. No late applications will be accepted for this Funding Opportunity Announcement
-
Nutrition Obesity Research Centers (NORCs) (P30 Clinical Trial Optional)
(RFA-DK-19-002)
National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Date(s): October 23, 2019 and June 2, 2020, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Silvio O. Conte Digestive Diseases Research Core Centers (P30 Clinical Trial Optional)
(RFA-DK-19-004)
National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Date(s): November 1, 2019 and July 1, 2021, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Kidney Technology Development Research Education Program (R25 Clinical Trial Not Allowed)
(RFA-DK-19-006)
National Institute of Diabetes and Digestive and Kidney Diseases
Application Receipt Date(s): August 6, 2019
-
Conduct Studies to Establish More Targeted Durations of Use for Certain Approved Antimicrobial New Animal Drugs in Food Animals (U01 Clinical Trial Required)
(RFA-FD-19-007)
Food and Drug Administration
Application Receipt Date(s): May 20, 2019, by 11:59 PM Eastern Time.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date.
Late applications will not be accepted for this FOA.
-
Implementation of the Animal Feed Regulatory Program Standards (U18 Clinical Trial Not Allowed)
(RFA-FD-19-021)
Food and Drug Administration
Application Receipt Date(s): May 20, 2019, by 11:59 PM Eastern Time.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date.
Late applications will not be accepted for this FOA.
-
Medical Rehabilitation Research Resource (P2C Clinical Trial Optional)
(RFA-HD-20-004)
Eunice Kennedy Shriver National Institute of Child Health and Human Development
National Institute on Deafness and Other Communication Disorders
National Institute of Nursing Research
National Institute of Neurological Disorders and Stroke
National Center for Complementary and Integrative Health
National Institute of Biomedical Imaging and Bioengineering
Application Receipt Date(s): June 27, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Disparities Elimination through Coordinated Interventions to Prevent and Control Heart and Lung Disease Risk (DECIPHeR) (UG3/UH3 Clinical Trial Optional)
(RFA-HL-20-003)
National Heart, Lung, and Blood Institute
Application Receipt Date(s): May 17, 2019, by 5:00 PM local time of applicant organization.
All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.
-
Disparities Elimination through Coordinated Interventions to Prevent and Control Heart and Lung Disease Risk (DECIPHeR) - Research Coordinating Center (RCC) (U24 Clinical Trial Not Allowed)
(RFA-HL-20-004)
National Heart, Lung, and Blood Institute
Application Receipt Date(s): May 17, 2019 by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
-
BLOODSAFE: Research to enhance availability of safe blood for patients with severe anemia and hemorrhagic conditions in low or lower-middle income countries (LLMICs) in Sub-Saharan Africa (UG3/UH3 Clinical Trial Optional)
(RFA-HL-20-009)
National Heart, Lung, and Blood Institute
Application Receipt Date(s): May 20, 2019, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.
-
BLOODSAFE: Research to enhance availability of safe blood for patients with severe anemia and hemorrhagic conditions in low or lower-middle income countries (LLMICs) in Sub-Saharan Africa - Data Coordinating Center (DCC) (U24 Clinical Trial Not Allowed)
(RFA-HL-20-010)
National Heart, Lung, and Blood Institute
Application Receipt Date(s): May 20, 2019 by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on this date.